Tenderwize
Zurück zur Suche

Open-house Lenograstim rebate agreement

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 30, 2027 · 493 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-30 - Lenograstim

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is restricted to pharmaceutical undertakings for the relevant product, with seat and authorisation requir...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Conclusion of rebate agreements for the active substance Lenograstim under an open-house procedure.
  • Supply of pharmaceutical products (CPV 33600000).
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for Lenograstim pharmaceutical products in Germany, led by Techniker Krankenkasse with HEK and hkk participating. The notice states no exclusivity, no individual negotiations, and uniform terms for all eligible pharmaceutical companies. Contracting can occur throughout the term, but the agreement ends no later than 31.12.2027. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, with portal communication used for questions. No contract value is stated.

Risiken

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is restricted to pharmaceutical undertakings for the relevant product, with seat and authorisation requir...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house Lenograstim rebate agreement

Open-house contract for pharmaceutical rebate agreements under Section 130c(1) SGB V for the active substance Lenograstim. Scope is nationwide in Germany. The lot information comes from structured data and the notice text.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Dec 2025 - Dec 2027

Kategorie

Pharmaceutical products

Frist

Deadline Dec 30, 2027

Vergabedetails

Veröffentlichungsdatum
23 Apr 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
282722-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3